Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
The purpose of this study is to determine the maximum tolerated concentration (MTC) of
 bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate
 without rHuPH20 administered SC, the optimal dose of rHuPH20 to deliver bisphosphonate SC at
 MTC, and to compare the PK of SC administered bisphosphonate at MTC with optimal dose rHuPH20
 to bisphosphonate alone.
Inclusion Criteria:

 -  Male or female volunteers 18 to 60 years of age, inclusive.

 -  Intact normal skin in the area intended for administration.

 -  Adequate venous access in both upper extremities.

 -  Dental examination by an appropriately trained professional within 14 days of
 administration demonstrating no signs, symptoms, or risk factors of osteonecrosis of
 the jaw (ONJ).

 -  Vital signs (BP, HR, temperature, respiratory rate) within normal range or, if out of
 range, assessed by the Investigator as not clinically significant and it is mutually
 agreed by both Investigator and Sponsor Medical Monitor that the subject need not be
 excluded from the study for this reason.

 -  Electrocardiogram within normal range or if out of range, assessed by the Investigator
 as not clinically significant and it is mutually agreed by both Investigator and
 Sponsor Medical Monitor that the subject need not be excluded from the study for this
 reason.

 -  Within 14 days prior to administration, metabolic panel (e.g., sodium, potassium,
 chloride, bicarbonate, BUN, creatinine, glucose, calcium, AST, ALT, alkaline
 phosphatase, total bilirubin, albumin, and total protein) and complete blood count
 within the laboratory normal reference range or, if out of range, assessed by the
 Investigator as not clinically significant and it is mutually agreed by both
 Investigator and Sponsor Medical Monitor that the subject need not be excluded from
 the study for this laboratory value.

 -  A negative serum or urine pregnancy test (if female of child-bearing potential) within
 14 days of study drug administration.

 -  Female subjects of child-bearing potential must agree to be currently practicing
 effective birth control or abstinence and agree to continue to do so for at least 30
 days after duration of their time on study.

 -  Decision-making capacity and willingness and ability to comply with the requirements
 for full completion of the trial.

 -  Signed, written IRB/EC-approved informed consent.

 Exclusion Criteria:

 -  Lower extremity edema.

 -  Lower extremity pathology that could interfere with any protocol-specified outcome
 assessment (e.g., cellulitis, lymphatic disorder or prior surgery, pre-existing pain
 syndrome, auxiliary lymph node dissection, etc.).

 -  Creatinine clearance < 60 mL/min (Cockcroft-Gault formula).

 -  Any risk factor for bisphosphonate-related renal toxicity including by not limited to
 known predisposition to or history of renal insufficiency or renal failure,
 hypertension, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and
 subjects receiving known nephrotoxic drugs.

 -  Dehydration Grade 2 or higher based on NCI CTCAE V3.0.

 -  Known parathyroid gland dysfunction or any other disease that could lower blood
 calcium levels.

 -  Known history and/or electrocardiographic evidence of atrial fibrillation.

 -  Known allergy to any hyaluronidase.

 -  Bisphosphonate treatment within preceding six months.

 -  Known allergy or intolerance to any bisphosphonate.

 -  Pregnancy or breast-feeding woman.

 -  Known clinically significant cardiovascular, gastrointestinal, hepatic, neurological,
 psychiatric, endocrine, cancer, HIV infection, diabetes mellitus, intercurrent illness
 such as influenza, or other major systemic disease that would unduly risk the
 subject's safety or interfere with the interpretation of results.

 -  Participation in a study of any investigational drug or device within 30 days of
 enrollment in this study.